ClinicalTrials.gg
RecruitingNCT06889688Updated Apr 23, 2026

Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer

A Phase 3 interventional study of Camrelizumab+Apatinib+Eribulin and Physician's choice chemotherapy in Breast Cancer Stage IV and Triple -Negative Breast Cancer, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Recruiting at 7 sites in China. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-23.

Primary conditionTriple Negative Breast NeoplasmsRegistry: Breast NeoplasmsReclassifiedWhy we changed it
Registry
Breast Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Triple Negative Breast Neoplasms
Why
  1. The study's listed conditions name Triple Negative Breast Neoplasms, a narrower term within Breast Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
246
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies testing camrelizumab in Triple Negative Breast Neoplasms — 11 open to participants now, 12 under way, 4 of them phase 3. camrelizumab · Triple Negative Breast Neoplasms.

Planned enrollment
6th of 21
246 · median 90
Started
2025
with 2 others
Phase 3
5 of 21
3 open now
Primary completion
2028-12
later than 11 of 11 live
Registered
19th of 21
by date
Lead sponsor
1 of 21
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Among the 21 studies testing camrelizumab in Triple Negative Breast Neoplasms, this one is the 6th largest by planned enrollment, is one of 3 that started in 2025, is one of 5 in phase 3, reaches primary completion later than 11 of the 11 other live ones, and was the 19th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

11 of the 21 studies testing camrelizumab in Triple Negative Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

About camrelizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing camrelizumab in Triple Negative Breast Neoplasms, or all of them as a file.
02

Study summary

This study evaluates the efficacy and safety of camrelizumab, apatinib, and eribulin versus physician's choice chemotherapy in advanced TNBC.Primary Objectives: Assess improvements in progression-free survival (PFS) and overall survival (OS).Secondary Objectives: Compare objective response rate (ORR), disease control rate (DCR), clinical benefit rate (CBR), duration of response (DoR), time to response (TTR), two-year OS rate, biomarker analysis, and quality of life (QoL).Safety: Assess and compare adverse event incidence and severity.

Read the detailed description

This study aims to evaluate the efficacy and safety of the triplet regimen compared to physician's choice chemotherapy as a later-line treatment for advanced triple-negative breast cancer (TNBC). 1. Primary Objectives and Endpoints: To determine whether the combination of camrelizumab, apatinib, and eribulin improves progression-free survival (PFS) and overall survival (OS) compared to investigator's choice chemotherapy in advanced TNBC. 2. Secondary Objectives and Endpoints: To compare the following clinical parameters between the camrelizumab, apatinib, and eribulin combination and investigator's choice chemotherapy for advanced TNBC: -Objective response rate (ORR) Disease control rate (DCR) Clinical benefit rate (CBR) Duration of response (DoR) Time to response (TTR) Two-year overall survival rate (2-year OS rate) Biomarker analysis Quality of life (QoL) analysis 3.Safety Evaluation: Comparison of the incidence and severity of adverse events between the two groups.

03

Conditions studied

  • Breast Cancer Stage IV
  • Triple -Negative Breast Cancer

Browse trials for

Keywords

  • Advanced Triple-Negative Breast Cancer
  • Immunotherapy
04

In context

Triple Negative Breast Neoplasms Reclassified

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

This study's planned enrollment of 246 is above the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.

Browse Triple Negative Breast Neoplasms studies →

Lead sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University is the lead sponsor of 485 studies on the registry; 279 are open to participants now.

Compared within Triple Negative Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Breast Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject voluntarily agrees to participate in this study and signs an form (ICF).
  2. Female subjects aged ≥18 and ≤70 years on the date of signing the ICF.
  3. confirmed advanced triple-negative breast cancer (TNBC), defined as ER-negative (IHC ER-positive percentage \<1%), PR-negative (IHC PR-positive percentage \<1%), and -negative (IHC-/+, or IHC++ but FISH/CISH-), with at least one per v1.1 criteria.
  4. Patients who have received at least 1 and up to 4 lines of prior systemic therapy for or locally advanced unresectable triple-negative breast cancer (TNBC) with disease progression. Prior systemic therapy (including at least 1 and /adjuvant chemotherapy) must include at least a taxane or anthracycline. Subjects who relapse within 6 months after completion of neoadjuvant/adjuvant chemotherapy are considered as having failed first-line therapy.
  5. Capable of swallowing tablets.
  6. performance status of 0-1.
  7. Expected survival ≥12 weeks.
  8. Adequate function of vital organs, meeting the following criteria (without the use of blood products or growth factors during the screening period): (ANC) ≥1.5×10⁹/L. count ≥100×10⁹/L. ≥9 g/dL. Serum albumin ≥3 g/dL. Thyroid-stimulating hormone (TSH) ≤ (if abnormal, T3 and T4 levels should be assessed; subjects with normal T3 and T4 levels are eligible). Total ≤1.0×ULN (for subjects with Gilbert's syndrome or liver metastases, total bilirubin ≤1.5×ULN). and AST ≤1.5×ULN (for subjects with liver metastases, ≤3×ULN). Alkaline phosphatase (ALP) ≤2.5×ULN. Renal function within 7 days prior to the first dose: serum creatinine ≤1.5×ULN or ≥60 mL/min.
  9. Women of agree to use highly effective starting at least 7 days prior to the first dose and continuing for 24 weeks after the last dose. A negative serum pregnancy test is required within 7 days prior to the first dose.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with untreated active or .
  2. Participation in any other interventional clinical trial within 28 days prior to the first dose.
  3. History of severe allergic reactions to other monoclonal antibodies.
  4. Receipt of other antitumor therapies within 28 days prior to the first dose.
  5. Uncontrolled hypertension despite antihypertensive medication (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg).
  6. Prior treatment with , Tim-3, or LAG-3 antibodies, or T-cell co-stimulatory therapies (previous use of PD-1 or PD-L1 antibodies is allowed).
  7. Prior treatment with anti-angiogenic agents or eribulin chemotherapy.
  8. Presence of any active disease or a history of autoimmune disease (including but not limited to autoimmune hepatitis, interstitial pneumonitis, uveitis, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, or hypothyroidism). Subjects with vitiligo, or childhood asthma that has fully resolved without intervention in adulthood, may be included. Subjects with asthma requiring medical intervention with bronchodilators are excluded.
  9. Uncontrolled cardiac clinical symptoms or diseases, including: Heart failure classified as Class II or higher. Unstable angina. Myocardial infarction within the past year. supraventricular or ventricular arrhythmias requiring treatment or intervention.
  10. Urinalysis indicating proteinuria ≥++ or confirmed 24-hour urinary protein ≥1.0 g.
  11. Known hereditary or acquired bleeding or thrombotic disorders (e.g., hemophilia, coagulopathy, thrombocytopenia, hypersplenism).
  12. Congenital or acquired immunodeficiency (e.g., infection).
  13. Receipt of a within 4 weeks prior to or during the study period.
  14. Allergy or to the drugs.
  15. Underwent surgery within 3 months prior to enrollment or anticipated need for major surgical procedures during the study period.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
246 participants (estimated)

Study arms

  • Experimental
    Experimental Group

    Camrelizumab (200 mg, IV, Day 1) + Apatinib (250 mg, PO, QD) + Eribulin (1.4 mg/m², IV, Day 1 and Day 8) administered in 21-day cycles.

    Drug: Camrelizumab+Apatinib+Eribulin

  • Active comparator
    Control Group

    Physician's Choice Chemotherapy

    Drug: Physician's choice chemotherapy

Interventions

07

What researchers measure

Primary outcomes

  1. Progression-Free Survival

    Disease evaluation will be performed according to RECIST v1.1 criteria.

    Time frame: Time from enrollment to the occurrence of predefined events, including disease progression or death, whichever came first, assessed up to 60 months.

  2. Overall Survival

    Death from any cause.

    Time frame: From date of randomization until the date of death from any cause, assessed up to 120 months.

Secondary outcomes

  1. Objective Response Rate

    The percentage of patients in different groups whose tumor size reduction, meets the criteria for complete response (CR) or partial response (PR).

    Time frame: From date of randomization until the date of first documented CR or PR, whichever came first, assessed up to 12 months.

  2. Disease control rate

    Proportion of patients achieving CR, PR, or stable disease (SD).

    Time frame: From date of randomization until the date of first documented CR, PR or SD, assessed up to 12 months.

  3. Clinical Benefit Rate

    Proportion of patients achieving CR, PR, or SD.

    Time frame: From date of randomization until the date of first documented CR, PR or SD for more than 6month, assessed up to 18 months.

  4. Duration of Response

    Time from the first assessment showing CR or PR to the first occurrence of progressive disease (PD) or death from any cause.

    Time frame: Time from the first assessment showing CR or PR to the first occurrence of PD or death from any cause, whichever came first, assessed up to 120 months.

  5. Time to Response

    Time from randomization to the first occurrence of CR or PR.

    Time frame: Time from randomization to the first occurrence of CR or PR, whichever came first, assessed up to 6 months

  6. Two-Year Overall Survival Rate

    Proportion of patients alive two years after randomization.

    Time frame: Two years after randomization.

  7. Safety Evaluation

    Comparison of the incidence and severity of adverse events between the two groups.

    Time frame: From randomization to 30 days after the last dose of study treatment.

Other outcomes

  1. Tumor and Peripheral Blood Biomarker Analysis

    This analysis aims to identify biomarkers that predict treatment response, resistance, and prognosis in advanced triple-negative breast cancer (TNBC). Tumor Biomarker Analysis: Genetic and Molecular Profiling: Whole-exome sequencing (WES), RNA sequencing, and proteomics to identify mutations, gene expression patterns, and protein markers related to treatment response. Immune Microenvironment Assessment: Immunohistochemistry (IHC) and multiplex immunofluorescence to evaluate tumor-infiltrating lymphocytes (TILs), PD-L1 expression, and other immune-related markers. Peripheral Blood Biomarker Analysis: Measurement of inflammatory and immunomodulatory cytokines to assess systemic immune response.

    Time frame: Before treatment and after 2 cycles (each cycle is 21 days) of treatment, or disease progression.

  2. QoL

    Quality of life assessment will be conducted using the EORTC QLQ-BR23 questionnaire. Raw scores will be linearly transformed to a standardized scale ranging from 0 to 100 points.

    Time frame: At baseline upon enrollment and every 2cycles (each cycle is 21 days) of treatment, from date of randomization until the patient exits the study due to disease progression, adverse events, whichever came first, assessed up to 60 months.

08

Study locations

5 of 7 sites recruiting
  • Sun Yat-sen Memorial Hospital
    Guangzhou, Guangdong, China
    Recruiting
    • Jieqiong Liu, M.D., Ph.D. · Contactliujieqiong01@163.com · +86-020-34071156
    • Jieqiong Liu, M.D., Ph.D · Principal investigator
  • The Affiliated Hospital of Guizhou Medical University
    Guiyang, Guizhou, China
    Recruiting
    • Shu Liu, M.D., Ph.D. · Contact+86-851-86855119
    • Shu Liu, M.D., Ph.D · Principal investigator
  • Wuhan Union Hospital of China
    Wuhan, Hubei, China
    Not yet recruiting
    • Yanxia Zhao, M.D., Ph.D. · Contact+86-027-85726114
    • Yanxia Zhao, M.D., Ph.D · Principal investigator
  • Yichang Central People's Hospital
    Yichang, Hubei, China
    Recruiting
    • Yuyan Tan, M.D., Ph.D. · Contact+86-0717-6484621
    • Yuyan Tan, M.D., Ph.D · Principal investigator
  • Xiangya Hospital of Central South University
    Changsha, Hunan, China
    Not yet recruiting
    • Kejing Zhang, M.D., Ph.D. · Contact+86-0731-82650001
    • Kejing Zhang, M.D., Ph.D · Principal investigator
  • The Central Hospital Of Yong Zhou
    Yongzhou, Hunan, China
    Recruiting
    • Sijuan Ding · Contact+86-0746-6565666
    • Sijuan Ding, M.D., Ph.D · Principal investigator
  • Changhai Hospital of Shanghai
    Shanghai, China
    Recruiting
    • Hengyu Li, Dr. · Contact+86 21 31166666
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Dec 2028, 46 months after the start.

Of 60 phase 3 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 103. This study's planned 46 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2025
First posted
Mar 21, 2025
StartActual
Feb 21, 2025
Primary completionEst.
Dec 31, 2028
CompletionEst.
Jun 1, 2029
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06889688
Responsible party
Jieqiong Liu, M.D., Ph.D. (Professor, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University) — Principal investigator
First posted
Mar 21, 2025
Start date
Feb 21, 2025
Primary completion
Dec 31, 2028 (estimated)
Completion
Jun 1, 2029 (estimated)
Last update
Apr 23, 2026

Study contacts

Jieqiong Liu, M.D., Ph.D.
Contact
liujieqiong01@163.com
+86-020-34071156

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Camrelizumab · Apatinib · Eribulin

Start the discussion